Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Bullboard Posts
Comment by geos571on Aug 20, 2015 10:15am
149 Views
Post# 24035334

RE:News..Topical includes DMSO in Patent

RE:News..Topical includes DMSO in Patent

Ibufoam should be available in a spray can and have a similar price point to Voltaren. It should also be sold OTC . Nuvo has the cash reserves to bring this market and should without a partner .

 

 

About IBUFOAM
IBUFOAM has been developed to treat acute and chronic pain conditions such as sprains and strains and osteoarthritis (OA).  IBUFOAM is a topical ibuprofen foam formulation that combines a transdermal carrier DMSO with 5% the NSAID ibuprofen and delivers the active drug through the skin directly to the site of inflammation and pain.
Read more at https://www.stockhouse.com/news/press-releases/2015/08/20/nuvo-research%C2%AE-announces-u-s-patent-for-topical-foamed-formulations-that#zgivkTBeRq2rKQF7.99
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse